Confluence Life Sciences' Series B - III Round

Confluence Life Sciences raised a round of funding on April 19, 2016.

Confluence Life Sciences (CLS) is developing treatments for animal and human diseases with a pipeline of programs based on kinase targets and approaches to challenging kinase targets. The company is d…

Articles about Confluence Life Sciences' Series B - III Round: